HLB-LSK

Elevar Therapeutics is a clinical-stage biopharmaceutical company and a subsidiary of the South Korean conglomerate HLB Co., Ltd. The company is dedicated to developing and commercializing innovative therapies for cancer, with a primary focus on its lead candidate, rivoceranib. Rivoceranib is a highly selective VEGFR-2 inhibitor that has shown efficacy in various solid tumors and is currently under regulatory review in the U.S. for the first-line treatment of hepatocellular carcinoma in combination with camrelizumab. Elevar also recently acquired lirafugratinib, a potent FGFR2 inhibitor, which is under priority review for cholangiocarcinoma. Headquartered in New Jersey, Elevar leverages its global network to advance its pipeline through late-stage clinical trials and toward commercialization.